search for




 

The Associations Between Liraglutide and Risk of Acute Pancreatitis in Patients with Type 2 Diabetes : A Meta-analysis
J. Kor. Soc. Health-syst. Pharm. 2020;37:471-484
Published online November 30, 2020;  https://doi.org/10.32429/jkshp.2020.37.4.006
© 2020 Korean Society of Health-System Pharmacists

Young Hoon Leea, Jung Kyu Parkb and Hye Duck Choia†

College of Pharmacy, Yeungnam University, 280 Daehak-ro, Gyeongsan, Gyeongsangbuk-do, 38541, Republic of Koreaa
Department of Pharmacy, Yeungnam University Hospital 170 Hyeonchung-ro, Nam-gu, Daegu, 42415, Republic of Koreab
Correspondence to: 최혜덕 Tel: 053-810-2815 E-mail: choihd@yu.ac.kr
Received June 23, 2020; Revised July 21, 2020; Accepted October 21, 2020.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background : Acute pancreatitis is an important and serious disease even with a relatively low incidence. Also, previous studies suggest that the coexistence of Type 2 diabetes and acute pancreatitis is closely related to an increased risk of death. However, the risk of acute pancreatitis in patients treated with liraglutide, a GLP-1 receptor agonist, has not been adequately evaluated.
Objective : This meta-analysis was conducted to investigate the association between the liraglutide and acute pancreatitis in patients with Type 2 diabetes.
Methods : Forty-one studies were assessed, and the results of the included studies were quantitatively integrated using the meta-analysis. The incidence of the liraglutide-related acute pancreatitis was estimated. As a sub-group analysis, four studies were assessed for comparing the liraglutide-treated groups and the control groups (placebo or other antidiabetic drugs except GLP-1 receptor agonists).
Results : The incidence of acute pancreatitis was 0.4% (95% confidence interval (CI) 0.3%-0.5%). The risk of acute pancreatitis was not significantly different between the liraglutide-treated groups and the control groups (odds ratio=1.412; 95% CI 0.290-6.866).
Conclusion : The incidence of liraglutide-related acute pancreatitis was relatively low and not additionally increased compared to the other antidiabetic drugs. We suggest that this meta- analysis is meaningful as evidence for the clinical use of liraglutide.
Keywords : Liraglutide, Acute pancreatitis, Meta-analysis, Type 2 diabetes


November 2020, 37 (4)